Bristol-Myers Squibb: Process for Data Collection
 
Process for Data Collection

We collect environmental data from our manufacturing, R&D, and distribution facilities throughout the world.

Verification

Bristol-Myers Squibb conducts two types of review and verification of our Environmental Health and Safety performance. We contract with a third party to assess the elements and performance of our corporate EHS evaluation process. This assessment provides an independent opinion about our program’s ability to provide competent, reliable and objective information about Bristol-Myers Squibb’s compliance programs and EHS performance.

The assessment includes document reviews, data collection, site visits and interviews with key personnel within our company.

Normalizing Data

Our 2015 Environmental Performance Goals are absolute. However, we have also provided normalized data in our Key Performance Indicator Table. We normalized to worldwide sales and report in U.S. dollars. We acknowledge the shortcomings of this approach. Several factors, including inflation, currency fluctuations and licensing agreements, can affect sales without impacting production levels or environmental operating results. Nonetheless, sales dollars apply to all our operations, at all of our divisions worldwide and represent the best measure currently available to us.

Acquisitions and Divestitures

We include facilities in our data collection and reporting systems for full calendar years only. Newly opened facilities are included in the first full calendar year of operation. New acquisitions are included within two full calendar years. If a facility is divested or closed, data from the facility are included through the last full calendar year it was part of Bristol-Myers Squibb.

U.S. SARA 313 Releases

Bristol-Myers Squibb facilities in the United States report annually on releases of toxic chemicals to the air, water and land. The toxic release inventory is required under Section 313 of the Superfund Amendments and Reauthorization Act (SARA). Releases are defined broadly under SARA Section 313 to include the off-site transfer of chemicals in addition to air emissions and wastewater discharges.

The U.S. government's TRI database contains information for all facilities covered by this regulation. Our currently active facilities in this database include:

  • Humacao, Puerto Rico
  • Lawrenceville, New Jersey
  • Manati, Puerto Rico
  • New Brunswick, New Jersey
  • Syracuse, New York
 
 
 
 


You are leaving BMS.com to go to the Amylin Job Search and application tool. IMPORTANT TO NOTE: This may require a separate login and password than what is used for the Bristol-Myers Squibb search and application process.